Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile

ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer

insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer

Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

Industry Veteran Jonathan Freeman, Ph.D. Joins ARTBIO As Chief Business Officer

Candid Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th

Marea Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Tango Therapeutics Appoints Sung Lee to Board of Directors

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

Seaport Therapeutics Presents Data Further Validating GlyphTM Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Seaport Therapeutics to Present at 2025 RBC Capital Markets Healthcare Private Company Conference

insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

BAMF Health Doses First Patient in Promising New Prostate Cancer Alpha Radioligand Therapy Clinical Trial

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Seaport Therapeutics to Present at Stifel 2025 Healthcare Conference

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Tango Therapeutics Announces $225 Million Financing

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform 

Synnovation to Present SNV1521 (PARP1) Phase 1 Study Results at the European Medical Oncology (ESMO) Congress 2025 and Announces Clinical Collaboration with DualityBio to Evaluate the Combination of SNV1521 with Duality’s HER3 ADC, DB-1310

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Fierce Biotech Names Trace Neuroscience a “Fierce 15” Biotech Company of 2025

Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree